Today is World Mental Health Day, a time to raise awareness of mental health issues around the world and to mobilize efforts in support of mental health. The day provides an opportunity for all stakeholders working on mental health issues to talk about their work and what more needs to be done to make mental health care a reality for people worldwide. #MentalIllnessAwarenessWeek
Neurocrine Biosciences
Biotechnology Research
San Diego, California 64,101 followers
You Deserve Brave Science
About us
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. Review our Community Guidelines: https://bit.ly/3L8M8hx *in collaboration with AbbVie
- Website
-
http://www.neurocrine.com
External link for Neurocrine Biosciences
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 1992
- Specialties
- Movement Disorders, CNS, Neurology, and Endocrinology
Locations
-
Primary
San Diego, California, US
-
12780 El Camino Real
San Diego, CA 92130, US
Employees at Neurocrine Biosciences
-
Matt Crawford, MBA
Regional Specialty Manager - Long Term Care at Neurocrine Biosciences
-
Annette Dowsing
-
Hector Ortega
Award-Winning Key Account Manager | I Help Biopharma Engage High Value Customers: C-Suite, HCPs, IDNs, KOLs | Boost Market Share, Drive Sales…
-
Lori Hodsoll, PACS
Regional Patient Access Manager
Updates
-
Physician assistants are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. This Physician Assistant Week, we honor their contributions to patient care. #PAweek #PAsGoBeyond
-
Neurocrine is proud to support Physician Assistant Week and to recognize the vital role PAs play in addressing patient needs. PAs are valuable contributors to the mental health care system, delivering high-quality, comprehensive care to individuals in need. Their expertise and compassion make a difference every day. #PAweek #PAsGoBeyond
-
Today is World Cerebral Palsy Day, a time to bring together people living with cerebral palsy, their families and supporters. Dyskinetic Cerebral Palsy is a form of cerebral palsy that is associated with a range of developmental delays, difficulties with physical function and involuntary movements. The Kinect-DCP Study is currently enrolling children, adolescents and adults, ages 6 – 70. The study is designed to determine if an investigational treatment can potentially improve involuntary movements that are difficult to control (dyskinesia) due to cerebral palsy (CP). Learn more: KinectDCPResearchTrial.com
-
We are excited to announce that enrollment for our 2025-2027 University of Southern California - Neurocrine Biosciences Postdoctoral Fellowship Program will open on October 10th. The fellowship program will provide training activities that support company goals, as well as developmental opportunities through broad-based, hands-on experience and mentorships that integrate our fellows into several strategic, medical initiatives. To learn more, register for one of our two upcoming informational webinars: https://lnkd.in/gYXtXkrr Wednesday, October 9 from 5:00PM – 6:00PM PT/ 8:00PM – 9:00PM ET Wednesday, October 23 from 5:00PM – 6:00PM PT/ 8:00PM – 9:00PM ET
-
At #MDSCongress today, we announced interim results from the ongoing open-label KINECT®-HD2 study. Data from this interim analysis highlights the long-term treatment of adults with chorea associated with Huntington’s disease, including results on concomitant use of antipsychotic therapy. Read more: https://lnkd.in/g5xCUhaV International Parkinson and Movement Disorder Society
-
We are proud to support National Advanced Practice Providers Week and recognize the critical role that APPs provide in caring for patients with mental health conditions, including patients living with tardive dyskinesia (TD), a persistent, involuntary movement disorder associated with the use of antipsychotic medication. APPs enhance the delivery of high-quality, comprehensive care to individuals in need. Thank you, APPs. We acknowledge and appreciate your important role in enhancing access and improving the quality of care to patients. #NationalAPPWeek
-
Great Place to Work and Fortune have recognized Neurocrine Biosciences as a Great Place to Work®. This prestigious ranking is based on employee feedback and reflects our strong culture, commitment to brave science and dedication to patients. Join the team that works each day to relieve suffering for people with great needs, but few options: https://lnkd.in/gUudctFv
-
We are proud to be ranked #7 on the 2024 Fortune Best Workplaces in Biopharma™ list. This recognition reinforces our commitment to work relentlessly to bring hope to the patients we serve. Want to join our team? Check out our available positions and apply today: https://lnkd.in/gUudctFv
-
Today we announced positive top-line data for a Phase 2 clinical study of NBI-1117568, an investigational, oral, muscarinic M4 selective agonist in development as a potential treatment for schizophrenia. NBI-1117568 is the first compound in the Neurocrine Biosciences' broad muscarinic portfolio with the potential to advance to Phase 3 studies. Learn more: https://lnkd.in/gCv_BxMZ